Experimental cell therapy takes on glioblastoma
NCT ID NCT05660369
First seen Nov 20, 2025 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This early-stage trial tests a new treatment called CARv3-TEAM-E T cells for people with glioblastoma, a serious brain cancer that has come back. The therapy uses the patient's own immune cells, modified in a lab to better attack the cancer, and is given directly into the brain fluid. The main goal is to find a safe dose and see if the approach is feasible in 21 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital Cancer Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CARv3-TEAM-E T cells (a type of immune cell therapy)
What this could lead to
If it works, this could point toward a new treatment for glioblastoma, a tough brain cancer.
What could go wrong
This is a very early, small Phase 1 trial (21 people) focused on safety, not yet on effectiveness. The therapy may cause serious side effects or not shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.